Медицинские средства защиты на основе вирусспецифических антител для экстренной профилактики и лечения заболевания, вызванного вирусом Эбола - Журнал Терапевтический архив № 11 Инфекционные болезни 2019
Медицинские средства защиты на основе вирусспецифических антител для экстренной профилактики и лечения заболевания, вызванного вирусом Эбола
Сизикова Т.Е., Лебедев В.Н., Борисевич С.В. Медицинские средства защиты на основе вирусспецифических антител для экстренной профилактики и лечения заболевания, вызванного вирусом Эбола. Терапевтический архив. 2019; 91 (11): 98–104. DOI: 10.26442/00403660.2019.11.000164
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Вирус Эбола (представитель рода Ebolavirus семейства Filoviridae) является этиологическим агентом особо опасного заболевания, летальность которого достигает 90%. Важнейшими компонентами спектра средств экстренной профилактики и лечения заболевания, вызванного вирусом Эбола, являются препараты на основе вирусспецифических антител (плазма реконвалесцентов, гетерологичные иммуноглобулины, моноклональные антитела). Целью настоящего обзора является анализ эффективности медицинских средств защиты на основе вирусспецифических антител для экстренной профилактики и лечения заболевания, вызванного вирусом Эбола. В обзоре рассмотрено использование различных классов препаратов на основе вирусспецифических антител и возможное совершенствование их состава и стратегии применения при экстренной профилактике и лечении заболевания, вызванного вирусом Эбола.
Ключевые слова: вирус Эбола, геморрагическая лихорадка, специфические антитела, плазма крови реконвалесцентов, гетерологичные иммуноглобулины, моноклональные антитела, экстренная профилактика и лечение.
Keywords: Ebola virus, hemorrhagic fever, specific antibodies, convalescent’s plasma of blood, geterologic immunoglobulin, monoclonal antibodies, special prophylactic and current.
Ключевые слова: вирус Эбола, геморрагическая лихорадка, специфические антитела, плазма крови реконвалесцентов, гетерологичные иммуноглобулины, моноклональные антитела, экстренная профилактика и лечение.
________________________________________________
Keywords: Ebola virus, hemorrhagic fever, specific antibodies, convalescent’s plasma of blood, geterologic immunoglobulin, monoclonal antibodies, special prophylactic and current.
Список литературы
1. Эпидемиология, профилактика и лабораторная диагностика болезни, вызванной вирусом Эбола. Практическое руководство. Под ред. Поповой А.Ю., Кутырева В.В. Саратов: Буква, 2015: 244 с. [Epidemiology, prophylaxis, and laboratory diagnostics of Ebola virus disease. Edited by Popova AYu, Kutyreva VV. Saratov: Letter, 2015: 244 р (In Russ.)].
2. Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba N, Soropogui B, Sow MS. Emergence of Zaire Ebola Virus Disease in Guinea. New Eng J Med. 2014;378:1418-25. https://doi.org/10.1056/NEJMoa1404505
3. Li J, Duan HJ, Chen HY, et al. Age and Ebola viral load correlate with mortality and survival time in 288 Ebola virus disease patients. Int J Infect Dis. 2016;42:34-9. https://doi.org/ 10.1016/j.ijid.2015.10.021
4. WHO URL: http://apps.who.int/gho/data/node.ebola-sitrep
5. Emond RT, Evans B, Bowen ET, Lloyd G. A case of Ebola virus infection. Br Med J. 1977;2(6086):541-4. PMID: 890413
6. Mupapa K, Massambla M, Ribadi K. Treatment of Ebola virus hemorrhagic fever with.blood transfusions from convalescent patients. J Infect Dis. 1999;179(1):18-23. https://doi.org/10.1086/514298
7. Van Griensven J, Edwards T, de Lamballerie X, et al. Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. New Eng J Med. 2016;374(1):33-42. https://doi.org/ 10.1056/nejmoa1511812
8. Wolf T, Kann G, Becker S, et al. Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. Lancet. 2015;385(9976):1428-35. https://doi.org/10.1016/S0140-6736(14)62384-9
9. Uyeki TM, Mehta AK, Davey RT, et al. Clinical Management of Ebola Virus Disease in the United States and Europe. New Eng J Med. 2016;374(7):636-46. https://doi.org/10.1056/ nejmoa1504874
10. Маркин В.А., Михайлов В.В., Краснянский В.П., Борисевич И.В., Фирсова И.В. Разработка принципов экстренной профилактики и лечения лихорадки Эбола. Вопросы вирусологии. 1997;42(1):31-4 [Markin VA, Mikhailov VV, Krasnyanskiy VP, Borisevich IV, Firsova IV. Development of principlesof special prophylaxis and current of Ebola fever. Voprosy virusologii. 1997;42(1):31-4 (In Russ.)].
11. Dowall SD, Rayner E, Hall G, Carbonnelle C, Raoul H, Coxon R, Abdulla IA, Hewson R. Development of a Cost-effective Ovine Polyclonal Antibody-Based Product, EBOTAb, to Treat Ebola Virus Infection. J Infect Dis. 2016;1124-33. https://doi.org/10. 1093/infdis/jiv565
12. Jarhling PB, Geisbert JB, Swearengen JR, Larsen T, Geiabert TW. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J Infect Dis. 2007;196(2):400-3. https://doi.org/10.1086/520587
13. Dowall SD, Jacquot F, Landon J, Rayner E, Hall G, Carbonnelle C, Raoul H, Pannetier D, Cameron I, Coxon R, Abdulla IA, Hewson R, Carroll MW. Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product. Scientific Reports 7. 2017;4099:1-15. https://doi.org/10.10 38/s41598-017-03910-7
14. Донченко В.В., Лебедев В.Н., Маркин В.А., Фирсова И.В. Эффективность вирусспецифических белков в иммуногенезе при экспериментальной лихорадке Марбург. Вопросы вирусологии. 1996;5:216-8 [Donchenko VV, Lebedev VN, Markin VA, Firsova IV. The effectivity of virusspecific proteins in immunogenesis with experimental Marburg fever. Voprosy virusologii. 1996;41(5):216-8 (In Russ.)].
15. Краснянский В.П., Михайлов В.В., Борисевич И.В., Градобоев В.Н., Евсеев А.А., Пшеничнов В.А. Получение гипериммунной лошадиной сыворотки против вируса Эбола. Вопросы вирусологии. 1995;40(3):138-40 [Krasnyanskiy VP, Mikhailov VV, Borisevich IV, Gradoboev VN, Evseev AA, Pshenichnov VA. Preparation of hyperimmune horse serum against Ebola virus. Voprosy virusologii. 1995;40(3):138-40 (In Russ.)].
16. Борисевич И.В., Михайлов В.В., Краснянский В.П., Градобоев В.Н., Лебединская Е.В., Потрываева Н.В. Разработка и изучение свойств иммуноглобулина против лихорадки Эбола. Вопросы вирусологии. 1995;40(6):270-3 [Borisevich IV, Mikhailov VV, Krasnyanskiy VP, Gradoboev VN, Lebedinskaya EV, Potryvaeva NV. Development and study of the properties of immunoglobulin against Ebola. Voprosy virusologii. 1995;40(6):270-3 (In Russ.)].
17. Борисевич И.В., Черникова Н.К., Марков В.И., Краснянский В.П., Борисевич С.В., Рождественский Е.В. Опыт применения специфического иммуноглобулина из сыворотки крови лошадей в качестве средства экстренной профилактики лихорадки Эбола. Вопросы вирусологии. 2017;1:25-9 [Borisevich IV, Chernikova NK, Markov VI, Krasnianskiy VP, Borisevich SV, Rozhdestvenskiy EV. An experience in the clinical use of specific immunoglobulin from horse blood serum for prophylaxis of Ebola haemorrhagic fever. Voprosy virusologii. 2017;62(1):25-9 (In Russ.)]. doi: 10.18821/0507-4088-2017-62-1-25-29
18. Pyankov OV, Setoch YX, Bodnev SA, Edmonds JH, Pyankova OG, Pyankov SA, Pali G, Belford S, Lu L, La M, Lovrecz G, Volchkova VA, Chappell KJ, Waterson D, Marsh G, Young PB, Agafonov AA, Farmer JF, Volchkov VE, Suhbier A, Khromykh AA. Successful post-exposure prophylaxis of Ebola infected non-human primates using Ebola glycoprotein-specific equine IgG. Scientific Reports. 2017;7:1-8. https://doi.org/ 10.1038/srep.41537
19. WHO Guidelines for the production, control and regulation of snake antivenom immunoglobulins. Avaiable from: http://www.who.int/bloodproducts/snake_antivenoms/snakeantivenomguide/en// Accepted Oct.2016.
20. Dye JM, Wu H, Hooper JW, Khurana S, Kuehne AI, Coile EM, Ortiz R, Fuentes S, Herbert AS, Golding H, Bakken RA, Brannan JM, Kwilas SA, Sullivan EJ, Luke TC, Smith G, Glenn G, Li W, Ye L, Yang C, Compans RW, Tripp RA, Jiao JA. Production of potent fully human polyclonal antibodies against Ebola Zaire virus in transchromosomal cattle. Scientific Reports 6. 2016;6:1-9. https://doi.org/10.1038/srep 24897
21. Choi WY, Hong KJ, Hong JE, Lee WJ. Progress of vaccine and drug development for Ebola preparedness. Clin Exp Vaccine Res. 2015;4(1):11-6. https://doi. org/10.7774/cevr.2015.4.1.11
22. Olinger GGJr, Pettitt J, Kim D, Working C, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, Pauly M, Whaley KJ, Lear CM, Biggins JE, Scully C, Hensley L, Zeitlin L. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci USA. 2012;109(44):18030-5. https://doi.org/10.1073/pnas.1213709109
23. Qiu X, Audet J, Wong G, Pillet S, Bello A, Cabral T, Strong JE, Plummer F, Corbett CR, Alimonti JB, Kobinger GP. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med. 2012;4(138):1-12. https://doi.org/10.1126/scitranslmed.3003876
24. Haque A, Hober D, Blondiaux J. Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks. Antimicrob Agents Chemother. 2015;59(10):5892-902. https://doi.org/10.1128/aac.01105-15
25. Sayburn A. WHO gives go ahead for experimental treatments to be used in Ebola outbreak. BMJ. 2014;349:1. https://doi.org/10.1136/bmj.g5161
26. Zhang Q, Gui M, Niu X, He S, Wang R, Feng Y, Kroeker A, Zuo Y, Wang H, Wang Y, Li J, Li C, Shi Y, Shi X, Gao G, Xiang Y, Qiu X, Chen L, Zhang L. Potent neutralizing monoclonal antibodies against Ebola virus infection. Sci Reports. 2016;6:1-15. https://doi.org/10.1038/srep25856
27. Holtsberg FW, Shulenin S, Vu H, Howell KA, Patel SJ, Gunn B, Karim M, Lai JR, Frei JC, Nyakatura EK, Zeitlin L, Douglas R, Fusco ML, Froude JW, Saphire EO, Herbert AS, Wirchnianski AS, Lear-Rooney CM, Alter G, Dye JM, Glass PJ, Warfield KL, Aman MJ. Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses. J Virol. 2015;90(1):266-78. https://doi.org/10.1128/jvi.02171-15
28. Keck ZY, Enterlein SG, Howell KA, Vu H, Shulenin S, Warfield KL, Froude JW, Araghi N, Douglas R, Biggins J, Lear-Rooney CM, Wirchnianski AS, Lau P, Wang Y, Herbert AS, Dye JM, Glass PJ, Holtsberg FW, Foung SKH, Aman MJ. Macaque monoclonal antibodies targeting novel conserved epitopes within filovirus glycoprotein. J Virol. 2016;90(1):279-91. https://doi.org/10.1128/jvi.02172-15
29. Wec AZ, Myakatura EK, Herbert AS, Howell KA, Holtsberg FA, Bakken RR, Mittler E, Christin JR, Shulenin S, Jangra RK, Bharrhan S, Kuehne AI, Bornholdt ZA, Flyak AI, Saphire EO, Crowe JEJr, Aman MJ, Dye JM, Lai JR, Chandran K. A “Trojan horse” bispecific-antibody strategy for broad protection against ebolaviruses. Science. 2016;354(6310):350-4. https://doi.org/10.1126/science.aag 3267
2. Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba N, Soropogui B, Sow MS. Emergence of Zaire Ebola Virus Disease in Guinea. New Eng J Med. 2014;378:1418-25. https://doi.org/10.1056/NEJMoa1404505
3. Li J, Duan HJ, Chen HY, et al. Age and Ebola viral load correlate with mortality and survival time in 288 Ebola virus disease patients. Int J Infect Dis. 2016;42:34-9. https://doi.org/ 10.1016/j.ijid.2015.10.021
4. WHO URL: http://apps.who.int/gho/data/node.ebola-sitrep
5. Emond RT, Evans B, Bowen ET, Lloyd G. A case of Ebola virus infection. Br Med J. 1977;2(6086):541-4. PMID: 890413
6. Mupapa K, Massambla M, Ribadi K. Treatment of Ebola virus hemorrhagic fever with.blood transfusions from convalescent patients. J Infect Dis. 1999;179(1):18-23. https://doi.org/10.1086/514298
7. Van Griensven J, Edwards T, de Lamballerie X, et al. Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. New Eng J Med. 2016;374(1):33-42. https://doi.org/ 10.1056/nejmoa1511812
8. Wolf T, Kann G, Becker S, et al. Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. Lancet. 2015;385(9976):1428-35. https://doi.org/10.1016/S0140-6736(14)62384-9
9. Uyeki TM, Mehta AK, Davey RT, et al. Clinical Management of Ebola Virus Disease in the United States and Europe. New Eng J Med. 2016;374(7):636-46. https://doi.org/10.1056/ nejmoa1504874
10. [Markin VA, Mikhailov VV, Krasnyanskiy VP, Borisevich IV, Firsova IV. Development of principlesof special prophylaxis and current of Ebola fever. Voprosy virusologii. 1997;42(1):31-4 (In Russ.)].
11. Dowall SD, Rayner E, Hall G, Carbonnelle C, Raoul H, Coxon R, Abdulla IA, Hewson R. Development of a Cost-effective Ovine Polyclonal Antibody-Based Product, EBOTAb, to Treat Ebola Virus Infection. J Infect Dis. 2016;1124-33. https://doi.org/10. 1093/infdis/jiv565
12. Jarhling PB, Geisbert JB, Swearengen JR, Larsen T, Geiabert TW. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J Infect Dis. 2007;196(2):400-3. https://doi.org/10.1086/520587
13. Dowall SD, Jacquot F, Landon J, Rayner E, Hall G, Carbonnelle C, Raoul H, Pannetier D, Cameron I, Coxon R, Abdulla IA, Hewson R, Carroll MW. Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product. Scientific Reports 7. 2017;4099:1-15. https://doi.org/10.10 38/s41598-017-03910-7
14. [Donchenko VV, Lebedev VN, Markin VA, Firsova IV. The effectivity of virusspecific proteins in immunogenesis with experimental Marburg fever. Voprosy virusologii. 1996;41(5):216-8 (In Russ.)].
15. [Krasnyanskiy VP, Mikhailov VV, Borisevich IV, Gradoboev VN, Evseev AA, Pshenichnov VA. Preparation of hyperimmune horse serum against Ebola virus. Voprosy virusologii. 1995;40(3):138-40 (In Russ.)].
16. [Borisevich IV, Mikhailov VV, Krasnyanskiy VP, Gradoboev VN, Lebedinskaya EV, Potryvaeva NV. Development and study of the properties of immunoglobulin against Ebola. Voprosy virusologii. 1995;40(6):270-3 (In Russ.)].
17. [Borisevich IV, Chernikova NK, Markov VI, Krasnianskiy VP, Borisevich SV, Rozhdestvenskiy EV. An experience in the clinical use of specific immunoglobulin from horse blood serum for prophylaxis of Ebola haemorrhagic fever. Voprosy virusologii. 2017;62(1):25-9 (In Russ.)]. doi: 10.18821/0507-4088-2017-62-1-25-29
18. Pyankov OV, Setoch YX, Bodnev SA, Edmonds JH, Pyankova OG, Pyankov SA, Pali G, Belford S, Lu L, La M, Lovrecz G, Volchkova VA, Chappell KJ, Waterson D, Marsh G, Young PB, Agafonov AA, Farmer JF, Volchkov VE, Suhbier A, Khromykh AA. Successful post-exposure prophylaxis of Ebola infected non-human primates using Ebola glycoprotein-specific equine IgG. Scientific Reports. 2017;7:1-8. https://doi.org/ 10.1038/srep.41537
19. WHO Guidelines for the production, control and regulation of snake antivenom immunoglobulins. Avaiable from: http://www.who.int/bloodproducts/snake_antivenoms/snakeantivenomguide/en// Accepted Oct.2016.
20. Dye JM, Wu H, Hooper JW, Khurana S, Kuehne AI, Coile EM, Ortiz R, Fuentes S, Herbert AS, Golding H, Bakken RA, Brannan JM, Kwilas SA, Sullivan EJ, Luke TC, Smith G, Glenn G, Li W, Ye L, Yang C, Compans RW, Tripp RA, Jiao JA. Production of potent fully human polyclonal antibodies against Ebola Zaire virus in transchromosomal cattle. Scientific Reports 6. 2016;6:1-9. https://doi.org/10.1038/srep 24897
21. Choi WY, Hong KJ, Hong JE, Lee WJ. Progress of vaccine and drug development for Ebola preparedness. Clin Exp Vaccine Res. 2015;4(1):11-6. https://doi. org/10.7774/cevr.2015.4.1.11
22. Olinger GGJr, Pettitt J, Kim D, Working C, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, Pauly M, Whaley KJ, Lear CM, Biggins JE, Scully C, Hensley L, Zeitlin L. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci USA. 2012;109(44):18030-5. https://doi.org/10.1073/pnas.1213709109
23. Qiu X, Audet J, Wong G, Pillet S, Bello A, Cabral T, Strong JE, Plummer F, Corbett CR, Alimonti JB, Kobinger GP. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med. 2012;4(138):1-12. https://doi.org/10.1126/scitranslmed.3003876
24. Haque A, Hober D, Blondiaux J. Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks. Antimicrob Agents Chemother. 2015;59(10):5892-902. https://doi.org/10.1128/aac.01105-15
25. Sayburn A. WHO gives go ahead for experimental treatments to be used in Ebola outbreak. BMJ. 2014;349:1. https://doi.org/10.1136/bmj.g5161
26. Zhang Q, Gui M, Niu X, He S, Wang R, Feng Y, Kroeker A, Zuo Y, Wang H, Wang Y, Li J, Li C, Shi Y, Shi X, Gao G, Xiang Y, Qiu X, Chen L, Zhang L. Potent neutralizing monoclonal antibodies against Ebola virus infection. Sci Reports. 2016;6:1-15. https://doi.org/10.1038/srep25856
27. Holtsberg FW, Shulenin S, Vu H, Howell KA, Patel SJ, Gunn B, Karim M, Lai JR, Frei JC, Nyakatura EK, Zeitlin L, Douglas R, Fusco ML, Froude JW, Saphire EO, Herbert AS, Wirchnianski AS, Lear-Rooney CM, Alter G, Dye JM, Glass PJ, Warfield KL, Aman MJ. Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses. J Virol. 2015;90(1):266-78. https://doi.org/10.1128/jvi.02171-15
28. Keck ZY, Enterlein SG, Howell KA, Vu H, Shulenin S, Warfield KL, Froude JW, Araghi N, Douglas R, Biggins J, Lear-Rooney CM, Wirchnianski AS, Lau P, Wang Y, Herbert AS, Dye JM, Glass PJ, Holtsberg FW, Foung SKH, Aman MJ. Macaque monoclonal antibodies targeting novel conserved epitopes within filovirus glycoprotein. J Virol. 2016;90(1):279-91. https://doi.org/10.1128/jvi.02172-15
29. Wec AZ, Myakatura EK, Herbert AS, Howell KA, Holtsberg FA, Bakken RR, Mittler E, Christin JR, Shulenin S, Jangra RK, Bharrhan S, Kuehne AI, Bornholdt ZA, Flyak AI, Saphire EO, Crowe JEJr, Aman MJ, Dye JM, Lai JR, Chandran K. A “Trojan horse” bispecific-antibody strategy for broad protection against ebolaviruses. Science. 2016;354(6310):350-4. https://doi.org/10.1126/science.aag 3267
2. Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba N, Soropogui B, Sow MS. Emergence of Zaire Ebola Virus Disease in Guinea. New Eng J Med. 2014;378:1418-25. https://doi.org/10.1056/NEJMoa1404505
3. Li J, Duan HJ, Chen HY, et al. Age and Ebola viral load correlate with mortality and survival time in 288 Ebola virus disease patients. Int J Infect Dis. 2016;42:34-9. https://doi.org/ 10.1016/j.ijid.2015.10.021
4. WHO URL: http://apps.who.int/gho/data/node.ebola-sitrep
5. Emond RT, Evans B, Bowen ET, Lloyd G. A case of Ebola virus infection. Br Med J. 1977;2(6086):541-4. PMID: 890413
6. Mupapa K, Massambla M, Ribadi K. Treatment of Ebola virus hemorrhagic fever with.blood transfusions from convalescent patients. J Infect Dis. 1999;179(1):18-23. https://doi.org/10.1086/514298
7. Van Griensven J, Edwards T, de Lamballerie X, et al. Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. New Eng J Med. 2016;374(1):33-42. https://doi.org/ 10.1056/nejmoa1511812
8. Wolf T, Kann G, Becker S, et al. Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. Lancet. 2015;385(9976):1428-35. https://doi.org/10.1016/S0140-6736(14)62384-9
9. Uyeki TM, Mehta AK, Davey RT, et al. Clinical Management of Ebola Virus Disease in the United States and Europe. New Eng J Med. 2016;374(7):636-46. https://doi.org/10.1056/ nejmoa1504874
10. Маркин В.А., Михайлов В.В., Краснянский В.П., Борисевич И.В., Фирсова И.В. Разработка принципов экстренной профилактики и лечения лихорадки Эбола. Вопросы вирусологии. 1997;42(1):31-4 [Markin VA, Mikhailov VV, Krasnyanskiy VP, Borisevich IV, Firsova IV. Development of principlesof special prophylaxis and current of Ebola fever. Voprosy virusologii. 1997;42(1):31-4 (In Russ.)].
11. Dowall SD, Rayner E, Hall G, Carbonnelle C, Raoul H, Coxon R, Abdulla IA, Hewson R. Development of a Cost-effective Ovine Polyclonal Antibody-Based Product, EBOTAb, to Treat Ebola Virus Infection. J Infect Dis. 2016;1124-33. https://doi.org/10. 1093/infdis/jiv565
12. Jarhling PB, Geisbert JB, Swearengen JR, Larsen T, Geiabert TW. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J Infect Dis. 2007;196(2):400-3. https://doi.org/10.1086/520587
13. Dowall SD, Jacquot F, Landon J, Rayner E, Hall G, Carbonnelle C, Raoul H, Pannetier D, Cameron I, Coxon R, Abdulla IA, Hewson R, Carroll MW. Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product. Scientific Reports 7. 2017;4099:1-15. https://doi.org/10.10 38/s41598-017-03910-7
14. Донченко В.В., Лебедев В.Н., Маркин В.А., Фирсова И.В. Эффективность вирусспецифических белков в иммуногенезе при экспериментальной лихорадке Марбург. Вопросы вирусологии. 1996;5:216-8 [Donchenko VV, Lebedev VN, Markin VA, Firsova IV. The effectivity of virusspecific proteins in immunogenesis with experimental Marburg fever. Voprosy virusologii. 1996;41(5):216-8 (In Russ.)].
15. Краснянский В.П., Михайлов В.В., Борисевич И.В., Градобоев В.Н., Евсеев А.А., Пшеничнов В.А. Получение гипериммунной лошадиной сыворотки против вируса Эбола. Вопросы вирусологии. 1995;40(3):138-40 [Krasnyanskiy VP, Mikhailov VV, Borisevich IV, Gradoboev VN, Evseev AA, Pshenichnov VA. Preparation of hyperimmune horse serum against Ebola virus. Voprosy virusologii. 1995;40(3):138-40 (In Russ.)].
16. Борисевич И.В., Михайлов В.В., Краснянский В.П., Градобоев В.Н., Лебединская Е.В., Потрываева Н.В. Разработка и изучение свойств иммуноглобулина против лихорадки Эбола. Вопросы вирусологии. 1995;40(6):270-3 [Borisevich IV, Mikhailov VV, Krasnyanskiy VP, Gradoboev VN, Lebedinskaya EV, Potryvaeva NV. Development and study of the properties of immunoglobulin against Ebola. Voprosy virusologii. 1995;40(6):270-3 (In Russ.)].
17. Борисевич И.В., Черникова Н.К., Марков В.И., Краснянский В.П., Борисевич С.В., Рождественский Е.В. Опыт применения специфического иммуноглобулина из сыворотки крови лошадей в качестве средства экстренной профилактики лихорадки Эбола. Вопросы вирусологии. 2017;1:25-9 [Borisevich IV, Chernikova NK, Markov VI, Krasnianskiy VP, Borisevich SV, Rozhdestvenskiy EV. An experience in the clinical use of specific immunoglobulin from horse blood serum for prophylaxis of Ebola haemorrhagic fever. Voprosy virusologii. 2017;62(1):25-9 (In Russ.)]. doi: 10.18821/0507-4088-2017-62-1-25-29
18. Pyankov OV, Setoch YX, Bodnev SA, Edmonds JH, Pyankova OG, Pyankov SA, Pali G, Belford S, Lu L, La M, Lovrecz G, Volchkova VA, Chappell KJ, Waterson D, Marsh G, Young PB, Agafonov AA, Farmer JF, Volchkov VE, Suhbier A, Khromykh AA. Successful post-exposure prophylaxis of Ebola infected non-human primates using Ebola glycoprotein-specific equine IgG. Scientific Reports. 2017;7:1-8. https://doi.org/ 10.1038/srep.41537
19. WHO Guidelines for the production, control and regulation of snake antivenom immunoglobulins. Avaiable from: http://www.who.int/bloodproducts/snake_antivenoms/snakeantivenomguide/en// Accepted Oct.2016.
20. Dye JM, Wu H, Hooper JW, Khurana S, Kuehne AI, Coile EM, Ortiz R, Fuentes S, Herbert AS, Golding H, Bakken RA, Brannan JM, Kwilas SA, Sullivan EJ, Luke TC, Smith G, Glenn G, Li W, Ye L, Yang C, Compans RW, Tripp RA, Jiao JA. Production of potent fully human polyclonal antibodies against Ebola Zaire virus in transchromosomal cattle. Scientific Reports 6. 2016;6:1-9. https://doi.org/10.1038/srep 24897
21. Choi WY, Hong KJ, Hong JE, Lee WJ. Progress of vaccine and drug development for Ebola preparedness. Clin Exp Vaccine Res. 2015;4(1):11-6. https://doi. org/10.7774/cevr.2015.4.1.11
22. Olinger GGJr, Pettitt J, Kim D, Working C, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, Pauly M, Whaley KJ, Lear CM, Biggins JE, Scully C, Hensley L, Zeitlin L. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci USA. 2012;109(44):18030-5. https://doi.org/10.1073/pnas.1213709109
23. Qiu X, Audet J, Wong G, Pillet S, Bello A, Cabral T, Strong JE, Plummer F, Corbett CR, Alimonti JB, Kobinger GP. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med. 2012;4(138):1-12. https://doi.org/10.1126/scitranslmed.3003876
24. Haque A, Hober D, Blondiaux J. Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks. Antimicrob Agents Chemother. 2015;59(10):5892-902. https://doi.org/10.1128/aac.01105-15
25. Sayburn A. WHO gives go ahead for experimental treatments to be used in Ebola outbreak. BMJ. 2014;349:1. https://doi.org/10.1136/bmj.g5161
26. Zhang Q, Gui M, Niu X, He S, Wang R, Feng Y, Kroeker A, Zuo Y, Wang H, Wang Y, Li J, Li C, Shi Y, Shi X, Gao G, Xiang Y, Qiu X, Chen L, Zhang L. Potent neutralizing monoclonal antibodies against Ebola virus infection. Sci Reports. 2016;6:1-15. https://doi.org/10.1038/srep25856
27. Holtsberg FW, Shulenin S, Vu H, Howell KA, Patel SJ, Gunn B, Karim M, Lai JR, Frei JC, Nyakatura EK, Zeitlin L, Douglas R, Fusco ML, Froude JW, Saphire EO, Herbert AS, Wirchnianski AS, Lear-Rooney CM, Alter G, Dye JM, Glass PJ, Warfield KL, Aman MJ. Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses. J Virol. 2015;90(1):266-78. https://doi.org/10.1128/jvi.02171-15
28. Keck ZY, Enterlein SG, Howell KA, Vu H, Shulenin S, Warfield KL, Froude JW, Araghi N, Douglas R, Biggins J, Lear-Rooney CM, Wirchnianski AS, Lau P, Wang Y, Herbert AS, Dye JM, Glass PJ, Holtsberg FW, Foung SKH, Aman MJ. Macaque monoclonal antibodies targeting novel conserved epitopes within filovirus glycoprotein. J Virol. 2016;90(1):279-91. https://doi.org/10.1128/jvi.02172-15
29. Wec AZ, Myakatura EK, Herbert AS, Howell KA, Holtsberg FA, Bakken RR, Mittler E, Christin JR, Shulenin S, Jangra RK, Bharrhan S, Kuehne AI, Bornholdt ZA, Flyak AI, Saphire EO, Crowe JEJr, Aman MJ, Dye JM, Lai JR, Chandran K. A “Trojan horse” bispecific-antibody strategy for broad protection against ebolaviruses. Science. 2016;354(6310):350-4. https://doi.org/10.1126/science.aag 3267
________________________________________________
2. Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba N, Soropogui B, Sow MS. Emergence of Zaire Ebola Virus Disease in Guinea. New Eng J Med. 2014;378:1418-25. https://doi.org/10.1056/NEJMoa1404505
3. Li J, Duan HJ, Chen HY, et al. Age and Ebola viral load correlate with mortality and survival time in 288 Ebola virus disease patients. Int J Infect Dis. 2016;42:34-9. https://doi.org/ 10.1016/j.ijid.2015.10.021
4. WHO URL: http://apps.who.int/gho/data/node.ebola-sitrep
5. Emond RT, Evans B, Bowen ET, Lloyd G. A case of Ebola virus infection. Br Med J. 1977;2(6086):541-4. PMID: 890413
6. Mupapa K, Massambla M, Ribadi K. Treatment of Ebola virus hemorrhagic fever with.blood transfusions from convalescent patients. J Infect Dis. 1999;179(1):18-23. https://doi.org/10.1086/514298
7. Van Griensven J, Edwards T, de Lamballerie X, et al. Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. New Eng J Med. 2016;374(1):33-42. https://doi.org/ 10.1056/nejmoa1511812
8. Wolf T, Kann G, Becker S, et al. Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. Lancet. 2015;385(9976):1428-35. https://doi.org/10.1016/S0140-6736(14)62384-9
9. Uyeki TM, Mehta AK, Davey RT, et al. Clinical Management of Ebola Virus Disease in the United States and Europe. New Eng J Med. 2016;374(7):636-46. https://doi.org/10.1056/ nejmoa1504874
10. [Markin VA, Mikhailov VV, Krasnyanskiy VP, Borisevich IV, Firsova IV. Development of principlesof special prophylaxis and current of Ebola fever. Voprosy virusologii. 1997;42(1):31-4 (In Russ.)].
11. Dowall SD, Rayner E, Hall G, Carbonnelle C, Raoul H, Coxon R, Abdulla IA, Hewson R. Development of a Cost-effective Ovine Polyclonal Antibody-Based Product, EBOTAb, to Treat Ebola Virus Infection. J Infect Dis. 2016;1124-33. https://doi.org/10. 1093/infdis/jiv565
12. Jarhling PB, Geisbert JB, Swearengen JR, Larsen T, Geiabert TW. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J Infect Dis. 2007;196(2):400-3. https://doi.org/10.1086/520587
13. Dowall SD, Jacquot F, Landon J, Rayner E, Hall G, Carbonnelle C, Raoul H, Pannetier D, Cameron I, Coxon R, Abdulla IA, Hewson R, Carroll MW. Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product. Scientific Reports 7. 2017;4099:1-15. https://doi.org/10.10 38/s41598-017-03910-7
14. [Donchenko VV, Lebedev VN, Markin VA, Firsova IV. The effectivity of virusspecific proteins in immunogenesis with experimental Marburg fever. Voprosy virusologii. 1996;41(5):216-8 (In Russ.)].
15. [Krasnyanskiy VP, Mikhailov VV, Borisevich IV, Gradoboev VN, Evseev AA, Pshenichnov VA. Preparation of hyperimmune horse serum against Ebola virus. Voprosy virusologii. 1995;40(3):138-40 (In Russ.)].
16. [Borisevich IV, Mikhailov VV, Krasnyanskiy VP, Gradoboev VN, Lebedinskaya EV, Potryvaeva NV. Development and study of the properties of immunoglobulin against Ebola. Voprosy virusologii. 1995;40(6):270-3 (In Russ.)].
17. [Borisevich IV, Chernikova NK, Markov VI, Krasnianskiy VP, Borisevich SV, Rozhdestvenskiy EV. An experience in the clinical use of specific immunoglobulin from horse blood serum for prophylaxis of Ebola haemorrhagic fever. Voprosy virusologii. 2017;62(1):25-9 (In Russ.)]. doi: 10.18821/0507-4088-2017-62-1-25-29
18. Pyankov OV, Setoch YX, Bodnev SA, Edmonds JH, Pyankova OG, Pyankov SA, Pali G, Belford S, Lu L, La M, Lovrecz G, Volchkova VA, Chappell KJ, Waterson D, Marsh G, Young PB, Agafonov AA, Farmer JF, Volchkov VE, Suhbier A, Khromykh AA. Successful post-exposure prophylaxis of Ebola infected non-human primates using Ebola glycoprotein-specific equine IgG. Scientific Reports. 2017;7:1-8. https://doi.org/ 10.1038/srep.41537
19. WHO Guidelines for the production, control and regulation of snake antivenom immunoglobulins. Avaiable from: http://www.who.int/bloodproducts/snake_antivenoms/snakeantivenomguide/en// Accepted Oct.2016.
20. Dye JM, Wu H, Hooper JW, Khurana S, Kuehne AI, Coile EM, Ortiz R, Fuentes S, Herbert AS, Golding H, Bakken RA, Brannan JM, Kwilas SA, Sullivan EJ, Luke TC, Smith G, Glenn G, Li W, Ye L, Yang C, Compans RW, Tripp RA, Jiao JA. Production of potent fully human polyclonal antibodies against Ebola Zaire virus in transchromosomal cattle. Scientific Reports 6. 2016;6:1-9. https://doi.org/10.1038/srep 24897
21. Choi WY, Hong KJ, Hong JE, Lee WJ. Progress of vaccine and drug development for Ebola preparedness. Clin Exp Vaccine Res. 2015;4(1):11-6. https://doi. org/10.7774/cevr.2015.4.1.11
22. Olinger GGJr, Pettitt J, Kim D, Working C, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, Pauly M, Whaley KJ, Lear CM, Biggins JE, Scully C, Hensley L, Zeitlin L. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci USA. 2012;109(44):18030-5. https://doi.org/10.1073/pnas.1213709109
23. Qiu X, Audet J, Wong G, Pillet S, Bello A, Cabral T, Strong JE, Plummer F, Corbett CR, Alimonti JB, Kobinger GP. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med. 2012;4(138):1-12. https://doi.org/10.1126/scitranslmed.3003876
24. Haque A, Hober D, Blondiaux J. Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks. Antimicrob Agents Chemother. 2015;59(10):5892-902. https://doi.org/10.1128/aac.01105-15
25. Sayburn A. WHO gives go ahead for experimental treatments to be used in Ebola outbreak. BMJ. 2014;349:1. https://doi.org/10.1136/bmj.g5161
26. Zhang Q, Gui M, Niu X, He S, Wang R, Feng Y, Kroeker A, Zuo Y, Wang H, Wang Y, Li J, Li C, Shi Y, Shi X, Gao G, Xiang Y, Qiu X, Chen L, Zhang L. Potent neutralizing monoclonal antibodies against Ebola virus infection. Sci Reports. 2016;6:1-15. https://doi.org/10.1038/srep25856
27. Holtsberg FW, Shulenin S, Vu H, Howell KA, Patel SJ, Gunn B, Karim M, Lai JR, Frei JC, Nyakatura EK, Zeitlin L, Douglas R, Fusco ML, Froude JW, Saphire EO, Herbert AS, Wirchnianski AS, Lear-Rooney CM, Alter G, Dye JM, Glass PJ, Warfield KL, Aman MJ. Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses. J Virol. 2015;90(1):266-78. https://doi.org/10.1128/jvi.02171-15
28. Keck ZY, Enterlein SG, Howell KA, Vu H, Shulenin S, Warfield KL, Froude JW, Araghi N, Douglas R, Biggins J, Lear-Rooney CM, Wirchnianski AS, Lau P, Wang Y, Herbert AS, Dye JM, Glass PJ, Holtsberg FW, Foung SKH, Aman MJ. Macaque monoclonal antibodies targeting novel conserved epitopes within filovirus glycoprotein. J Virol. 2016;90(1):279-91. https://doi.org/10.1128/jvi.02172-15
29. Wec AZ, Myakatura EK, Herbert AS, Howell KA, Holtsberg FA, Bakken RR, Mittler E, Christin JR, Shulenin S, Jangra RK, Bharrhan S, Kuehne AI, Bornholdt ZA, Flyak AI, Saphire EO, Crowe JEJr, Aman MJ, Dye JM, Lai JR, Chandran K. A “Trojan horse” bispecific-antibody strategy for broad protection against ebolaviruses. Science. 2016;354(6310):350-4. https://doi.org/10.1126/science.aag 3267
Авторы
Т.Е. Сизикова, В.Н. Лебедев, С.В. Борисевич
ФГБУ «48 Центральный научно-исследовательский институт» Минобороны России, Сергиев Посад, Россия
48 Central Scientific Research Institute, Sergiev Posad, Russia
ФГБУ «48 Центральный научно-исследовательский институт» Минобороны России, Сергиев Посад, Россия
________________________________________________
48 Central Scientific Research Institute, Sergiev Posad, Russia
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.